Antigenics, Inc., a biotechnology company, through its subsidiaries, engages in the development of technologies and products to treat cancers, infectious diseases, and autoimmune disorders, primarily based on immunological approaches. It offers Oncophage, a personalized therapeutic cancer vaccine candidate, which is in Phase 3 clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma. The company also offers AG-858, which is in Phase 2 clinical trial for the treatment of chronic myelogenous leukemia; AG-707, a therapeutic vaccine program that is in Phase 1 clinical trial for the treatment of genital herpes; Aroplatin, a liposomal chemotherapeutic, which is in Phase 1 clinical trial for the treatment of solid tumors and non-Hodgkin’s lymphoma; and QS-21, an adjuvant used in various vaccines, including hepatitis, lyme diseases, human immunodeficiency virus, influenza, cancer, and malaria. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York City.
LAST 1.78
نقطة الدخول بنهاية تداول اليوم
LAST 1.78
نقطة الدخول بنهاية تداول اليوم
